OMER - Earnings call transcript Q2 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, and welcome to today's earnings call for Omeros Corporation. At this time, all participants are in a listen-only mode. After the company's remarks, we will conduct a question-and-answer session. Please be advised that this call is being recorded at the company's request, and a replay will be available on today's – company's website for one week from today. I'll turn the call over to Jennifer Williams, Investor Relations for Omeros.

Jennifer Williams

you the thank today. and afternoon for call joining Good of you that call I'd forward-looking. remind some today the be the like to on that statements made will will be of management's change. and on subject based are and are statements expectations These as today only to beliefs involve uncertainties that statements actual the could and materially. differ to risks forward-looking cause company's All results and Please risk Form the SEC, in report these on risk factor XX-Q, with the was the company's report note today XX-K uncertainties. for forward-looking regarding of XXXX special to a section section refer statements discussion the filed which the of and factors annual and Form quarterly risks the company's on

would Omeros' Dr. to like call the Greg I Chairman over Demopulos, CEO. to Now, and turn

Greg Demopulos

appreciate I our be today's and you joining Thank our our Jennifer, and financial Nadia you, us Dac, Chief will Accounting update Commercial and through Chief We call. a second corporate quarter by both will results, Officer; and good joined everyone. Jacobsen, go for Mike Officer. afternoon

prepared human comments, of by complement, thrombotic fully I cell is an microangiopathy, our narsoplimab, have for FDA. review lectin MASP-X. enzyme license is of biologics associated update BLA or the treatment application, the of on the today hematopoietic questions. pathway priority time will MASP-X effector begin reserved antibody our with the for transplant under targeting monoclonal Following some we stem TA-TMA or

period. the for date review of PDUFA the Our extension XX BLA October FDA's is following

its closely working and We continue agency forward with FDA review. the look to completing

in a presentation Annual the to publicly Association. most pivotal European scientific XXXX medical trial across during Congress share a the podium recently of continue Hematology the and TA-TMA the of We variety venues, at from data June

immunoglobulin the stem A and of syndrome, and international TA-TMA. being hemolytic atypical and detailing have in manuscripts first or the trial leaders in indications, uremic role Narsoplimab pathway complement In journals, IgA the on publication or for elucidating evaluated in by second three science the also addition, to from findings is other pivotal cell nephropathy, the peer-reviewed authored the transplantation both been submitted lectin in aHUS, two MASP-X specifically COVID-XX.

sites are investigational ARTEMIS-IGAN Our prevalence we part the XXth number has Phase worldwide of adding China, of narsoplimab approximately pharmacodynamics and A the by on nephropathy IgA a month nephropathy pharmacology, be IgA activated presentation focused the in will of Chinese X in pathway given and sites. pharmacokinetics lectin Prague. of International Symposium on inhibition next trial XXX

trial Phase is Our ongoing. aHUS also X

providing therapeutic selected additional appears and the Quantum for due Collaborative trial. in trial foreseeable Healthcare be recent all the endemic. patients of inclusion COVID-XX and the the dispute. with that in be sponsored I-SPY data resurgence effective recent is identified, being in involvement trial need most is The individuals, began the become in variant only and for COVID COVID-XX Narsoplimab the trial Narsoplimab in COVID-XX inhibitor XXX,XXX part With other rising pandemic to severe by patients is run with complement evaluated an and COVID-XX that death as dosing part and in March. in in than can the unvaccinated no Omeros BARDA. it in the well and by is has infections Delta by might funded one speed drug throughout variants Quantum new cases beyond will and future of primarily The cases the to us the recovery the continues that sickest prevent daily COVID-XX show nationwide about Leap vaccinated U.S. both with particularly

COVID-XX we be announced drug results. trial has from previously efficacy and are will that and studied cohort from await we trials' and/or ventilation. were cohort had second Like the first. No all progressing were told COVID-XX optimistic the even patients on results than sicker we poor In to for the in patients. the narsoplimab Italy. We mechanical those risk initial Bergamo, factors are and that cohort in all this sufficient first patients of enrollment May, demonstrated of comorbidities cohort outcomes treated XX is patients in The the in graduate the the

died recovered, survived after cardiomyopathy, and dosing were began The a and In XX-year-old, XX fact, the including being preexisting had from XX complications X of were his initiation who deaths eight a days. of severely these were other intubated of treatment. XX patients to prior narsoplimab being discharged. narsoplimab failed two XX-year-old, so who treatments, Despite for ill, the All of steroids. intubated

from As a was in the peer-reviewed Bergamo publish the journal. the to plan we with patients, from results second cohort of done the cohort first data

and have our support We Omeros-Cambridge University shown at also coming severe peer-reviewed leading field the the continuing the work specifically early role of published OCXIR. our immunology. last the of worldwide for COVID-XX. in COVID an journal at we the was others OCXIR manuscript the and uniformly what research, frontiers COVID-XX are in central pathophysiology complement and pathway for and The pathway Center lectin the month play in inflammation lectin MASP-X A that MASP-X rationale research laboratories detailing from in Cambridge, and inhibiting or the data

them. and and incidence cause in infections narsoplimab's concomitant seen with increased is the role fungal including of Additional COVID-XX work underway, bacterial, viral of preventing potential identification the of often

We pathway to sequelae explore or of PASC. MASP-X in SARS-CoV-X, lectin role of the the also acute plan the post and

further for non-clinical our the are data manufacturing with of regarding around and discussions in COVID-XX generated ongoing All narsoplimab and and U.S. support governments clinical and international helpful narsoplimab. funding

revenue revenues financial quarter second million increase second were revenues. $X.X OMIDRIA the a quarter-over-quarter our million, from quarter's compared sales to This represents growth. last at XX% now results. $XX.X quarter of in Net look Let's

or $X.XX which per net Our the loss second was or of share, charges. $XX.X were million, for quarter $X.X million, share, non-cash $X.XX per

As equivalents and $XX.X cash in short-term of June million investments. we had XX, cash,

continued surgery used as a when and not an for restored that used management We Centers the posted separate to and Medicaid been been that by the determination OMIDRIA of have based qualifies pain for separately separate additional drugs. be credit quarter Medicare the OMIDRIA to non-opioid yet policy contractors payment centers, XXXX receivable, OMIDRIA. also and had through CMS have for largely of in its first under $XX available surgical million full this accounts last which administrative AFCs. or $XXX appropriate December allowing reimbursement grow Services, our the was made million CMS QX Medicare result payment to or confident line for that customers at-the-market. Revenues determination for on has ambulatory our CMS had the reimburse

throughout we we continue. outpatient and year corresponding month, result, a rule the OMIDRIA system, expect or its for momentum CMS to quarter, that saw As growth payments second the Last calendar issued sales proposed OPPS. prospective in XXXX

decision OMIDRIA qualifies the policy December payment regarding its confirmed CMS agency's again, for pain management non-opioid under that separate surgical Here drugs.

we Given tenure be policy which Chambers or since this continues continue OMIDRIA Prevent Legislatively, to receive is when that The in XXXX, make in in the payment XXXX, rule both NOPAIN used our short, CMS issued Act likely policy, the year. to and this in throughout CMS In been later the will separate of has has no Non-Opioids of endorsement in effect by to this expectation anticipate Nation change and the OPPS final and reimbursement Addiction CMS ASCs headway beyond. Congress. by

support, the co-sponsoring bill, and Act in NOPAIN key members leadership bicameral committees XX House the representatives rosters of jurisdiction The with grow, Now continue bipartisan to Senators both Senate. the that and has strong and including on and The XX

hospital The The Nadia and Surgeons, for a or Act our Officer, Chief outpatient health not College Importantly, Nadia? commercial few, management Association both and including Association, ASCs, and provide and of societies of also separate but American The Medical if of endorsed now Surgery Society American American Association, American The activities in on AdvaMed, The Council. an drugs The public by NOPAIN also the like Safety to when departments. Colleges organizations, Anesthesiologists, bill With that Nurses, National is OMIDRIA provide Technology Ambulatory update Commercial would for name major of Association, only narsoplimab. non-opioid Dac, The Medical medical will Center pain OMIDRIA passed Advanced payment The in

Nadia Dac

Thank the we're of narsoplimab quarter, sustained the segment, is the growing ambulatory to in strides separate revenue our call, in surgical Starting of Greg. be centers, of last by it's over prior for about ASCs. CMS current last of significant strong which the roughly to and but with increase payment, payment is restored hospital to has levels our largest volume separate quarter. make a delivering at of XX% last following December segment readiness over driven excited representing the loss separate recovery continued about with still OMIDRIA, the hospital XX% growth Since our those last business. half you, in we yet total Since decision in reimbursement OMIDRIA by have launch XX%

another groups our combined chains. operated quarter-over-quarter. two by we a successfully these equity and and we efforts XX% ASC volume six with specifically, to three with and and with May, second partnerships private an group groups the in has In total groups shared executed I contributed chain to overall private As momentum. equity quarter, with establishing you agreements ASC our owned of bringing this in ASCs categories chains drove PE More growth of

segments and with perception surgeons, in more of OMIDRIA OMIDRIA's physicians. We they the to insights complication major recent compelling advisory benefits as OMIDRIA most benefits. reducing use as with from strengthen continues favorable held two gaining Additionally, July, their cited congresses of rates groups different conjunction cataract these in by centers. experience May its in to gain in boards reasons were ophthalmology

with in The less summed in procedure that research devices. of Overall the there's to as this during deeper interviewed words, pupil pupil up where positioning quantitative including in and insight day With macular intra-operative work message CME, to of reduction can advisory with of likely. superior We as lower IFAs of breakthrough field May rates part days boards with in size, pain insights smoother our we've our complications, complication studies and syndrome the the where planned or clear had other on intra-operative this research studies. our a in as post-operative down OMIDRIA more goes surgeries it clinical making collecting majority surgery learn Advisers were cataract including the come use days these effect stability, at They OMIDRIA's complications without. year. of refine further impressed dug research expansion message any with late IFA, of the reduction and their We're into just operative OMIDRIA consistent demonstrated time significant from market surgeons later the the feedback with experience revealed OMIDRIA's fulfills more top challenges. similar helping versus to year. and potential evolve by advisory iritis of the a floppy partner The a world market and edema about our along that importance trial cited as The surgeons which surgeons published is iritis been the excellence board from surgery evidence. platform benefits real procedure to we achieve comments post-operative consistently. reduced have Specifically attendees. every iris both breakthrough dependable help cataract such surgeons been are extensive of post-operative those research cystoid role complications who excited our platform how reported in pupil OMIDRIA's for market utilized with distinction between part insights OMIDRIA or this OMIDRIA all CME, also shared for

sales transplantation, launch continuing to sales managers review The readiness. the These and our field we're XX% transplant and make further strong launch of represent on to experience including training allogeneic and narsoplimab, joined We've cell has refine transplant strategies managers of total in centers. development top hematology with medical oncology key our taken science with to of been FDA hiring field market the a the progress plans. U.S. the go-to-market with and deep managers now time Talented transplant existing extension volume. liaisons stem initiated. team have our focus Turning centers

access plans specific on educating well stakeholders the symptoms account ensure as focused of narsoplimab rapid and addition TA-TMA post-approval. to as they're creating In signs to to center on profiling,

inpatient gaining We on decision-makers, and and pharmacy our to barriers both insights product outpatient distribution minimizing time with access at of interactions continue valuable launch.

met can vials care be at add Our These excellence, outpatient narsoplimab such is of willingness from for to payers team and with Vice sites decision-makers bone and life-threatening for and four understanding systems committee and topics TA-TMA. a patients which to within indicated essential Professionals of disease, attended hours, a approval. transplant processes XX agendas Conference Presidents centers. XX of gaining as centers five Last marrow is ensuring anticipation the better P&T at Directors oncology, distribution we received of top therapeutics month, FDA pharmacy our ready, committee Pharmacy advanced and shipped the pharmacy generally where model

So feedback is to narsoplimab as with offers for approved their is FDA narsoplimab for to consistent previous after board product addition and Overall, ensure is timely comments. the on reviews no a profile their There market. advisory centers formularies. compelling TA-TMA

improvement is proposition response sick refined the to and XXX significant safety observed be further narsoplimab no for a have narsoplimab's barriers feedback in point a days strategy optimal population that safety with market coupled narsoplimab's survival no profile meaning a on this pricing our disease life-threatening and approved signal in and intersection we treatments. our from value Finally, consistent strong efficacy with the would with significant rates very is advisors with between hear proposition access we strong minimized. value patient focus The where pricing research

Another inhibitors back our are launch used with in are over to this bringing are coupled approval. upon pricing I'll label guide course considering of data other execute the narsoplimab that insight driven turn based that experience we the strategy With to indication. that, board, poised call is With we the that we've off Greg. compliment successfully on been the and of stakeholder

Greg Demopulos

you, Thank Nadia.

rest provide on I'll of pipeline. Now the an update our

MASP-X Our OMSXXXX, well. beyond cycle next enter management our progressing slated are summer. and narsoplimab antibody second MASP-X long-acting generation life also is the to programs clinic

our will a clinical greater once development be The I with OMSXXXX accelerating than frequency Phase current that Phase timeline. subcutaneously expect We Xa dosed is no to trial and plan conduct combination monthly.

oral their OMSXXXX, we're to to small are advancing and for addition look molecule inhibitors. forward in the and once-daily These being MASP-X our administration, narsoplimab designed we In joining OMSXXXX clinic.

of while forging targets multiple alternative conversion MASP-X the are around pathway B, in Omeros factor exclusive controls is MASP-X D, enzyme key Our CX and to rights D development. program of ahead, pathway MASP-X. alternative property on-track D. responsible pro-factor in the intellectual activator also factor is there the mature the factor for currently

Phase the MASP-X inhibitor is we and being single was controlled pharmacokinetic preliminary than from and expect evaluated once trial. quarter, at the OMSXXX tested double-blind monthly showing subcutaneously. that Last given X doses well frequent data, dose and trials again all OMSXXX dosing ascending Our tolerated a in placebo we no announced more results multiple pharmacodynamic

found production that growth molecules. Consistent deficient checkpoint in these is GPRXXX also results that observations, cancer by GPRXXX in expressed immune death GPRXXX part attenuated tumor of our B Finally, our immuno-oncology the granzyme let's killing interferon We enhances GPRXXX as turn controls program. T-cells central tumor a inhibitors broad such a of and TNF, platform. discovered certain deficiency immunity We've to GPCR plank GPRXXX, IL-X, of Exclusively mice. or to is pathway expression immune cells, production and inhibitors increased We're in and immunotherapy developing both know the GPRXXX around small intellectual antibody with of Omeros. as GPRXXX and in of around molecules. property GPRXXX exposure well inhibitors also and GPRXXX those cell of itself. molecule gamma as tumor novel target stimulating agents are reduces immunosuppressive exclusive as building phenotypes position abroad

maximize inhibitor So necessary used following we radiation be commonly and will believe that chemotherapy. tumor immune killing GPRXXX a to responses

We that immunotherapies rate. combined GPRXXX of also response could expect improve inhibitors cancer with be existing to

and IL-X example, improving next as with immunotherapies, inhibitors emerging rates. Keytruda combined Yervoy For response or adenosine well generation with as such again, inhibitors, GPRXXX as be could access

advance therapy other of and components our platform, Beyond CAR-T GPRXXX, we continue to oncology adoptive immuno programs. our including cell

over patent an Jacobsen, change to overview that, Accounting of programs With build estates to financial the that results. I'll call Officer our immune-oncology wholly the turn quarter could second Chief expect Mike new continue which We for both our around, we fundamentally approaches these broad landscape.

Mike Jacobsen

Thanks Greg.

million, for or Greg and million As the the revenues XX% second to quarter first from were OMIDRIA noted, total $XX.X increase an $X.X quarter.

quarter was Our $X.XX $X.X or million per includes net expenses share. for per the non-cash of share. loss $XX.X million or $X.XX This

and of cash general short-term As cash, $XX.X of million had we XX, equivalents available for investments June XXXX, operations.

a to reserves. allows certain borrow to baseline receivable borrowing available line have accounts receivable XX% after of accounts million also credit, of We which us base $XX our up

entered stock. in time-to-time, recall million may to March, we of agreement to up $XXX from us you an aftermarket sell common that allows sales As also into our

seen partially This second and decrease year. narsoplimab. the the increase to weekly sell-through for expenses October to steady quarter the our quarter, development Costs prior launch for a this first was to increase an in to seen of activities. expenses of a due of continue as and and due prepare to are million customers U.S. to have OMIDRIA manufacturing ASCs the million; $X.X timing quarter additional research we the increase costs level were During was at increase loss of of plan sales $XX.X X, second XXXX these payment. from separate offset and selling, The the we general in administrative by narsoplimab the

I costs manufacturing the current we $X.X States. approval with marketing was expense will certain narsoplimab million in the expensing United first obtain As quarter and Interest stated previously, we for are until that the are we quarter. consistent

As Greg strengthen. mentioned continuing scenario for reimbursement to a earlier Omeros

will expect the to use ramp-up, increase customer our our revenues we grow. further So of as ASC OMIDRIA base OMIDRIA customer's and their continues

Greg? TA-TMA hospital quarter should quarter ended for and XXXX. development of June remainder with hiring overall With increased Due million. managers. preparations in largely compared expect turn medical that, costs second narsoplimab quarter costs the the consistent expense to the related regional Greg. of back the I'll the are to expected the research quarter the increase year, our $X.X sales over throughout launch be at XX, the of SG&A Interest to support and to XXXX to call third and in We costs OMSXXXX. to additional clinical third increase costs to development for affairs

Greg Demopulos

questions. call Operator, let's Mike. to please Thanks open the

Operator

from of Geoff Bank First the from line Instructions] Meacham America. [Operator question comes of Okay.

line now Your is open.

Greg Harrison

This for Hi, Harrison guys. taking for Geoff. question. Greg our is Thanks on

that your would that we the then Just forward do as continue moving trial in things wanted would it as when expectations that really and you'd indication? to may take go expectations sense from think out? long to efficacy would to what before assuming like around get we you be data And thoughts as you that your far How to. reads that see I-SPY them convince it makes

Greg Demopulos

not a we trial Thanks. answer, are Well, with the not the they but at involved to Hi, sponsors timing would trial they don't in length. so the just They of all really the I-SPY have began that enrollment. it do they Omeros, Greg. may credibility preserve They but of keep sponsors a sense know first of where be with March. respect arm's trial. satisfying I enrolling in that I good And the can down number and meet of probably making picked of enrollment increasing. well are earlier but up over many that guess past for the new would into that the I those expect mean, recently how bit very again. are the that there, enrollment I question we I-SPY. how slowed infections the criteria I of a talked has of COVID-XX many as several about those think and would it The is months, hospital

as anything With hope is It in determination to that that respect initially that is done lack in see be we really soon have have sense good efficacy feasibility we we'll patients. look, done of our least it to share the cut to when make as we So, of heard there. be I studies showing by if ill appears to something quite and we don't a COVID have know, the there narsoplimab do of would They would with the to that a we complete to soon for they'll hear is But proceed from a we or we be effective others as information. haven't there. data at substantial appears we already data critically a been how for looking pretty think have us. what narsoplimab,

strength those So in the confident we're pretty data. of

– Italy, treated what do I-SPY aren't those different we in both slightly it's comes outside in out be have of as I-SPY. and in need patients Again, a enrolled that we of we're to U.S. case, the and I-SPY. the see on, sick what the required this counting Now, And see patient to I protocol The population. the to is as and it the we of on management that is we're that the trial, also deliver rigor trial would believe certainly of believe the counting the rigor data with we but narsoplimab. of

there any stop and you've got about me if question let So that. see

Greg Harrison

there the And you helpful. after forward would do funding? of you think one has to really that's Maybe you your that's about of results be or have in path idea had No, that follow-up. just talk commercially from I-SPY? that? be NIH something any would BARDA What with Or talks happen have likely been COVID-XX more government

Greg Demopulos

and the we narsoplimab we next supplement, say, move will IgA, we requirements studies manufacturing come and the more our fund as across up have do that the are here have What step. let's forward. make discussions – governments, and appropriate both we've other in broadly drug we the our the that No, more right. would discussions what support narsoplimab ongoing how our and as – clearly be narsoplimab to COVID-XX. manufacturing I those to cetera. that we I I manufacturing, discussions for priority order et focus areas – of capabilities additional be we're given just be opportunities the discussions for But And clinical we back would trials as be yes, challenged said, those think are because, for next are as ongoing. certainly expect, as main broadly scale ongoing think that What well already so, first if need be manufacturing moving we other the step with around available? And what is TA-TMA, international think U.S. Well, aHUS of of would us. increase of to use the data funding And in

the be So I to needs that think focus.

drug make be other Assuming in positive FDA who available to it. the need response talking or EUA to with in the certainly to I-SPY would approach some patients we about look trial,

Greg Harrison

helpful. Great, Thank that's you. very

Greg Demopulos

Greg Thanks,

Operator

from comes line Brozak Next of Steve from the WBB. question

now line is open. Your

Steve Brozak

questions. the Hi, taking thanks for

specific Just there given COVID. Thanks. OMIDRIA the into one obviously, the after clinical on the and the prepared and that. queue specifically believe a – quick And vis-à-vis you hop last terms in How given now? one, unfortunately, of COVID its do use you is to was reference back question, system I'll of resurgence resurgence

Greg Demopulos

look Thanks, with resurgence elective Well think Thanks. asking Steve. be by is what might I and I – to respect expect COVID. and how and those procedures you're affected

correct I'm ambulatory So I'll question PPE one that running or equipment, centers. answer in off that would major me. But elective protective the challenge I in initial that of which think base, to if we please keeping with we are respect procedures that through surgery nationally was personal had impediments the

although my that know I I readily would that be is So those expectation, PPE we challenges generally available. same don't expectation don't this, have my think

procedures. resurgence And happening that to in to and with cataract affect elective specifically would respect COVID I so would ASCs procedures, not a with expect what's meaningfully in the respect

procedures the will the be any can't I in still right, of of on what patient safety assess is what impact to seeing COVID, in ASCs. their response, very we're little patient's elective concern that around their there sort appears currently is want Now, setting undergo patients to OMIDRIA from but

if were see something question and or stop that me asking was that let was the even So it you else.

Steve Brozak

making I-SPY. with the question on forward again. I looking all direct Thanks that was actually the you're and appreciate response. and this the no, congratulations quarter exact that to progress Look, No, obviously

Greg Demopulos

Steve. Thanks

Operator

H.C. from Next Ram Selvaraju Wainwright. line the comes question of from

now open? is line Your

Ram Selvaraju

patients Real able on my narsoplimab do anticipate any very and COVID-XX; to Hi, Delta questions. in anecdotal quickly taking for do of infected specifically being with kind investigational work much the thanks variant? you

Greg Demopulos

enrolled that that and That's variant. are I who being variant, think include criteria the fact, their that the variant. criteria Delta in patients Delta exclusion includes trial the what's an not enrollment they those don't interesting that patients excluding expect not Ram. Delta question. I-SPY with meaning Thanks know in the do I I or have

Independent endothelial that is the expect So large narsoplimab much the What variant in virus, virus, the variant, virus. the resultant in part pathway of the and Delta in of And action the that variant, to would to being the that I SARS-CoV-X are Delta patients is though, that of in currently I-SPY going endothelial injury and the independent the due expect present would in I patients. really be any of mechanism injury. the enrolled lectin addresses right? narsoplimab are is of trial in be SARS-CoV-X original should variant of very that – the wholly activation the variant really of lambda

don't any any effect based of I the So the see role detrimental on or SARS-CoV-X on impact large writ in variant. narsoplimab

Ram Selvaraju

narsoplimab helpful. have sort for in very narsoplimab I-SPY kind a does additional specifically in foundation likely and of be which potential already Can regulatory other impact approval, get be the some might potential sense EUA? study The or standalone done, be you ease a scenario either to you Do routes, potential with in for TA-TMA? via that trial be any approval or work which the if us, on or basis. clinical potentially could perspective as That's indication approval positing a to for elucidate also of would approval, narsoplimab of EUA has this how there's use What for feedback probably the non-COVID-XX the on basis a a via EUA of in COVID-XX? need

Greg Demopulos

that Well, don't and from I-SPY if trial specific do and use that statement comments broad programs. Cathy all of in you With patients. look outcome COVID-XX more said throughout I we've appropriate, that. to be positive think, FDA a on FDA think discussions that Regulatory figure first, of let – see we that. the for Having any with promote that, that, Head given collaborative I make to of And the our that work we would years any label I'll how have we we available push had with be working all me and general stop the would with additional broadly out the communications of would would drug discuss think our hope I that make FDA, drugs. about has would that relationships not also that that to make I do that if would Melfi, or the I off that comment our around not how

Cathy Melfi

sort discussions said, are and with Thanks, it certainly that speak And into stem TMA, about yes, would specifics I without have do Greg. between we similarities given getting as Greg think the COVID-XX cell regulatory that now. about account agencies, really then and there taking make what we that But FDA can they say the into than that, Greg think said thing. for decisions to I you're that that and that's all other and of

Ram Selvaraju

question trial, just status And ARTEMIS sites release, online you on top-line enrollment kind timeline brought comment at great. in China? can of and last the additional the in of context all on data to being one the Okay, particularly updated any

Greg Demopulos

Yes. updates hi, We enrollment. yes, give We – don't on don't Ron.

We to year. the of – part next target at target latter are continuing data

We down whether that know But year. we're have COVID objective. if we're need of latter that we'll to before of hit see in happens We'll what we us if will number see next data That to a COVID is is factors as We – slowed part the again, able we'll targeting what with that the down us that have may in see how sites effect. to including slow any China; expand goes. see that.

Ram Selvaraju

Thank you.

Operator

the of line from comes Cantor Folkes Fitzgerald. Brandon with question Next

line is open. now Your

Brandon Folkes

congratulations Hi, on thanks quarter. having question, and me good for a

demand? find for narsoplimab a opportunity you read market that to still secondly, potential maybe before and pricing, TMA? just on on you maximize Could Thank PE stocking any new should have within view price Firstly, I comes narsoplimab in are out on pricing? this the quarter to Was going all you. then how there data on impact the to narsoplimab TA-TMA contracts. or And OMIDRIA was ASC or

Greg Demopulos

there was no your to stocking. first response In question, Yes.

So I'll to we get again I commercially come that that that we your On is that to indications, more not I think if and – to think get approved how to handle continue should answer it don't answer that work not question, those directly. TA-TMA the once second Brandon. I answered your and that other objective question, I and narsoplimab these for point. will through with if think know if try we that another

Brandon Folkes

No.

you think I – think it. answer I did

to the whether think I-Spy of that if read – just you're definitely data may get was you out compelling I to comes approval that it going directly, more ask positively think, price you you I there, get is, and the but in usage opportunities they TA-TMA and of understanding you're like it yes, sort approval opportunity sounds focus up. address on come Is that then, the fair? going as more my COVID, to next more sort

Greg Demopulos

smaller Yes. COVID-XX you've critically the I said population. as a part is And part overall subset the in even of I narsoplimab the have look, which studied It smaller focus is specifically of is. Remember think on the population a patients. ill think relatively – that subset is in TA-TMA. of and COVID-XX the that And we really Brendan COVID-XX hospitalized

do would that I best So These need numbers, other we approved again, thing be ones that work do focus to can we overall would we getting expect narsoplimab we and that would to the problems for nice but would to TA-TMA. well. think I at certainly be sort would that on is have, look – through, and

Brandon Folkes

the extra color. Great. Thanks appreciate Greg, so much.

Greg Demopulos

Thank you.

Operator

are time. turn There will call at Dimopoulos. to the further this back questions over Dr. I no also

Greg Demopulos

to the thank like we across time and everyone the operator, as how for you of the Thank are today. with programs. Have all appreciate We're up. commercial taking a our Omeros Okay. likelihood Omarosa's thank again us development support. the continued evening. your join In and the Well, us remainder at And really progress of pleased you achieving them milestones and our shaping always good year you. meantime of

Operator

participating. today's for This concludes conference you Thank call.

disconnect. now may You

Omeros (OMER) 10 Aug 212021 Q2 Earnings call transcript